866141-79-9

Upstream product

• 866141-78-8 1-[4-(6-cyclopropylmethyl-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylen-2-yl)-3-trifluoromethyl-phenyl]-ethanone 
• 866141-75-5 (S)-6-cyclopropylmethyl-2-bromo-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraazaacenaphthylene 
• 866141-77-7 2-trifluoromethyl-4-acetylphenylboronic acid pinacol ester 
• 866141-74-4 (S)-2-bromo-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraazaacenaphthylene 
• 129825-11-2 1-(4-chloro-3-(trifluoromethyl)phenyl)ethanone 
• 268547-53-1 3-bromo-7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine 
• 268547-52-0 5-methyl-1H-pyrazolo[4,3-b]pyridine-7-ol 
• 94220-38-9 7-chloro-5-methyl-1H-pyrazolo[4,3-b]-pyridine 

Relevant academic research and scientific papers

Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists

Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochemical properties, new tricyclic CRF1/sub